Caxton Associates (New York)’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-18,250
| Closed | -$1.3M | – | 526 |
|
|
2023
Q4 | $1.3M | Buy |
+18,250
| New | +$1.3M | 0.07% | 190 |
|
|
2020
Q3 | – | Sell |
-10,174
| Closed | -$710K | – | 415 |
|
|
2020
Q2 | $710K | Buy |
10,174
+4,924
| +94% | +$344K | 0.06% | 74 |
|
|
2020
Q1 | $238K | Buy |
+5,250
| New | +$238K | 0.04% | 299 |
|
|
2018
Q4 | – | Sell |
-4,963
| Closed | -$850K | – | 368 |
|
|
2018
Q3 | $850K | Sell |
4,963
-1,196
| -19% | -$205K | 0.06% | 122 |
|
|
2018
Q2 | $796K | Sell |
6,159
-264
| -4% | -$34.1K | 0.04% | 156 |
|
|
2018
Q1 | $662K | Buy |
+6,423
| New | +$662K | 0.03% | 195 |
|